Tirzepatide vs. Semaglutide: How They Compare in 2026

The short answer: Tirzepatide and semaglutide are different molecules. Semaglutide targets one gut-hormone receptor; tirzepatide targets two (GLP-1 and GIP) and produced larger average weight loss in trials, about 24.3% at the highest dose in SURMOUNT-1 versus about 15% for semaglutide in STEP 1. These are clinical-trial averages taken with diet and exercise; individual results vary. Both are given as weekly injections. Compounded versions of either are not FDA-approved.

How they work: one receptor vs. two

Semaglutide is a GLP-1 receptor agonist: it mimics the gut hormone GLP-1, which reduces appetite, slows stomach emptying, and helps regulate blood sugar. Tirzepatide does that too, but it is a dual GLP-1 and GIP receptor agonist, meaning it also activates a second incretin receptor (GIP). That second mechanism is the headline difference between the two drugs, and it is the leading explanation for why tirzepatide has produced larger average weight loss in head-to-head-style trial data. Both are once-weekly injections, and both work best paired with diet and activity changes rather than on their own.

What the trials showed

The clearest way to compare the two is by their pivotal weight-loss trials of the branded products. In SURMOUNT-1 (NEJM, 2022), participants on tirzepatide lost an average of about 24.3% of body weight over 72 weeks at the highest dose. In STEP 1 (NEJM, 2021), participants on semaglutide lost an average of about 15% over 68 weeks. Both trials combined the medication with lifestyle changes.

The practical takeaway: on the trial evidence, tirzepatide tends to deliver more weight loss on average, while semaglutide has a longer real-world track record and remains highly effective. Averages are not promises, though, and the right choice depends on your health history and how you tolerate the medication, which is a clinician's call.

Dosing and titration

Both medications are started low and stepped up slowly to limit side effects, a process called titration. Semaglutide for weight management titrates over months toward a maintenance dose, and tirzepatide titrates toward a maintenance dose of up to 15 mg weekly. Because both are escalated gradually, you should not expect the full trial-level effect in the first weeks, and rushing the dose usually means more nausea, not faster results. Our tirzepatide dosing guide walks through the tirzepatide titration schedule in detail.

Side effects

The two drugs share a broadly similar side-effect profile, and it is mostly gastrointestinal: nausea, diarrhea, constipation, and vomiting are the most common, and they are usually strongest right after starting or increasing the dose. Neither drug is clearly gentler for everyone; the main lever for tolerability is slow titration and staying hydrated. Both carry warnings that a provider will review with you, including a boxed warning about thyroid C-cell tumors seen in rodents. This is why both are prescription-only and require a licensed provider to decide whether treatment is appropriate for you.

Cost

Cost depends heavily on whether you use a compounded program or the branded product. Across the compounded telehealth programs we track, compounded tirzepatide generally runs a bit higher than compounded semaglutide because tirzepatide is the newer, dual-mechanism molecule. As one example of current pricing, MaxLife lists compounded tirzepatide at $195/mo ($150/mo on a 12-month plan) and compounded semaglutide at $175/mo ($135/mo on 12 months), with no membership fee. Branded Zepbound® (tirzepatide) and Wegovy® (semaglutide) are separate, FDA-approved products whose real cost depends on your insurance. Our tirzepatide cost guide breaks down the full pricing landscape.

How to choose

If maximum average weight loss on the trial evidence is the priority, tirzepatide is the stronger performer. If you value the longest real-world track record, semaglutide is well established. But the honest answer is that this is a medical decision, not a shopping decision: the right medication depends on your health history, other conditions, how you tolerate side effects, and what a licensed provider recommends. Whichever molecule you and your provider choose, the program you use still matters, because compounded versions are not FDA-approved and the compounding pharmacy is the real quality signal. See how the programs score in our 2026 rankings and how we weight them in our methodology.

The bottom line

Tirzepatide and semaglutide are different medications, not two names for the same thing. Tirzepatide's dual GLP-1 and GIP mechanism produced larger average weight loss in trials (about ~24.3% vs ~15%), while semaglutide has a longer real-world history; both are weekly injections with a similar, mostly gastrointestinal side-effect profile, and both are titrated up slowly. Compounded tirzepatide typically costs a little more than compounded semaglutide. Neither compounded version is FDA-approved, and which one fits you is a decision for a licensed provider.